Comparative Pharmacology
Head-to-head clinical analysis: SULF 15 versus SULFALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 15 versus SULFALAR.
SULF-15 vs SULFALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULF-15 is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (K_ATP), leading to cell membrane depolarization, calcium influx, and exocytosis of insulin.
Sulfamethoxazole is a sulfonamide that competitively inhibits dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism in bacteria.
150 mg orally twice daily for 14 days.
Oral: 500 mg to 1 g every 12 hours; extended-release: 1 g every 12 hours. Intravenous: 1 g every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 7-12 hours (prolonged in renal impairment up to 24-48 hours; clinical context: dosing interval adjustment needed for CrCl <30 mL/min)
Renal excretion accounts for 60-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 20-30% as metabolites and parent compound.
Renal: approximately 70-80% as unchanged drug and acetylated metabolite; biliary/fecal: 20-30%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)